Cargando…
High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines?
Guidelines for the treatment of schizophrenia limit the use of antipsychotic agents to clinically-established maximum doses. This acknowledges both the absence of additional efficacy of dopamine D2 receptor antagonists above a receptor occupancy threshold, and the increases in side effects that can...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436307/ https://www.ncbi.nlm.nih.gov/pubmed/34256637 http://dx.doi.org/10.1177/02698811211026456 |